



US006001844A

United States Patent [19]

Bakshi et al.

[11] Patent Number: **6,001,844**
 [45] Date of Patent: **Dec. 14, 1999**

[54] **4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS**

[75] Inventors: **Raman K. Bakshi**, Edison; **Soumya P Sahoo**, Old Bridge; **Richard L. Tolman**, Warren, all of N.J.

[73] Assignee: **Merck & Co., Inc.**, Rahway, N.J.

[21] Appl. No.: **09/029,926**

[22] PCT Filed: **Sep. 11, 1996**

[86] PCT No.: **PCT/US96/14564**

§ 371 Date: **Mar. 11, 1998**

§ 102(e) Date: **Mar. 11, 1998**

[87] PCT Pub. No.: **WO97/10217**

PCT Pub. Date: **Mar. 20, 1997**

Related U.S. Application Data

[60] Provisional application No. 60/003,826, Sep. 15, 1995.

[51] Int. Cl.⁶ **C07D 221/02**; A61K 31/435

[52] U.S. Cl. **514/284**; 514/255; 514/256; 514/262; 514/265; 514/266; 514/269; 514/272; 514/274; 514/275; 544/265; 544/266; 544/268; 544/276; 544/277; 544/301; 544/311; 544/312; 544/316; 544/317; 544/319; 544/320; 544/322; 544/323; 544/329; 544/332

[58] Field of Search 514/255, 256, 514/262, 265, 266, 269, 272, 274, 275, 284; 544/265, 266, 268, 276, 277, 301, 311, 312, 316, 317, 319, 320, 322, 323, 329, 332, 334, 335, 336, 408, 409; 546/77

[56] References Cited

U.S. PATENT DOCUMENTS

4,191,759	3/1980	Johnston	424/242
4,377,584	3/1983	Rasmusson et al.	424/258
4,760,071	7/1988	Rasmusson et al.	514/284
5,116,983	5/1992	Bhattacharya	546/14
5,151,429	9/1992	Rasmusson	514/284
5,302,621	4/1994	Kojima et al.	514/284
5,304,562	4/1994	Biollaz	514/284
5,565,467	10/1996	Batchelor et al.	514/284

FOREIGN PATENT DOCUMENTS

0 484 094	6/1992	European Pat. Off.
0 538 192	4/1993	European Pat. Off.
WO 92/16213	10/1992	WIPO
WO 94/07861	4/1994	WIPO
WO 95/07926	3/1995	WIPO

WO 95/07927 3/1995 WIPO.

OTHER PUBLICATIONS

Bakshi et al., 4-aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5a-reductases. *J. Med. Chem.* 38 (1995), pp. 3189-3192.

Tolman et al., "4-Methyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-N-aryl-carboxamides: An approach to combined androgen blockade"; Mar. 1997 issue of *J. Steroid Biochem & Molec. Bio.* vol. 60, No. 5-6 pp. 303-309.


Primary Examiner—Mukund J. Shah

Assistant Examiner—Brenda Coleman

Attorney, Agent, or Firm—Philippe L. Durette; Catherine D. Fitch; Melvin Winokur

[57] ABSTRACT

Compounds of structural Formula (I)



and pharmacologically acceptable salts and esters thereof possess 5α-reductase inhibitory activity. These compounds inhibit 5α-reductase type 1 and type 2. The compounds of structural Formula I are useful in the systemic, including oral, and parenteral, including topical, treatment and prevention of hyperandrogenic conditions including prostatic carcinoma, benign prostatic hyperplasia, acne vulgaris, seborrhea, androgenic alopecia (also called androgenetic alopecia) which includes male- and female-pattern baldness, female hirsutism, and prostatitis. A class of compounds of the present invention are also potent antiandrogens. The present invention also relates to novel compositions containing such compounds, methods of their use and methods of their manufacture.

13 Claims, No Drawings